---
schema_version: "secwatch.filing_event.v1"
accession: "0001558370-24-016391"
form_type: "8-K"
ticker: "BPTH"
cik: "0001133818"
company_name: "BIO-PATH HOLDINGS, INC."
filed_at: "2024-12-19T23:59:59+00:00"
generated_at: "2026-05-29T01:06:22.895396+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Bio-Path reports preclinical data for BP1001-A: enhanced insulin sensitivity in obesity/T2D models

## Summary
- BP1001-A reduced Grb2 protein expression in myoblast cells and increased p-AKT and p-FOXO-1 in myoblast and hepatoma cells.
- Data confirm mechanism of action via insulin/PI3K/AKT pathway; supports BP1001-A as obesity/T2D treatment.
- Animal studies initiated; if successful, Phase 1 clinical trial planned for 2025.
- CEO cites unmet need from existing weight-loss drugs failing in obese T2D patients.

## SEC filing metadata
- accession: 0001558370-24-016391
- form_type: 8-K
- ticker: BPTH
- cik: 0001133818
- company_name: BIO-PATH HOLDINGS, INC.
- filed_at: 2024-12-19T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1133818/000155837024016391/0001558370-24-016391-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1133818/000155837024016391/bpth-20241219x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001558370-24-016391
- JSON: https://secwatch.observer/filing/0001558370-24-016391.json
- Plain text: https://secwatch.observer/filing/0001558370-24-016391.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.